Alison Bauerlein Inogen Inc (INGN) insider trading activity

Alison Bauerlein is EVP, Finance, & CFO of Inogen Inc. Currently has a direct ownership of 33,902 shares of INGN, which is worth approximately $318,000. The most recent transaction as insider was on Dec 01, 2021, when has been sold 490 shares (Common Stock) at a price of $29.66 per share, resulting in proceeds of $14,533. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 33.9K

0% 3M change

0% 12M change

Total Value Held $318,000

Alison Bauerlein Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 01 2021	SELL Payment of exercise price or tax liability	$14,533 $29.66 p/Share	490 Reduced 1.42%	33,902 Common Stock
Dec 01 2021	BUY Exercise of conversion of derivative security	-	546 Added 1.56%	34,392 Common Stock
Sep 01 2021	SELL Payment of exercise price or tax liability	$37,311 $60.57 p/Share	616 Reduced 14.3%	3,691 Common Stock
Sep 01 2021	BUY Exercise of conversion of derivative security	-	799 Added 15.65%	4,307 Common Stock
Aug 02 2021	SELL Open market or private sale	$112,221 $80.33 p/Share	1,397 Reduced 26.99%	3,779 Common Stock
Aug 02 2021	BUY Exercise of conversion of derivative security	$53,840 $38.54 p/Share	1,397 Added 21.25%	5,176 Common Stock
Jul 30 2021	SELL Open market or private sale	$658,882 $80.01 p/Share	8,235 Reduced 68.55%	3,779 Common Stock
Jul 30 2021	BUY Exercise of conversion of derivative security	$317,377 $38.54 p/Share	8,235 Added 40.67%	12,014 Common Stock
Jul 27 2021	SELL Open market or private sale	$722,593 $75.02 p/Share	9,632 Reduced 71.82%	3,779 Common Stock
Jul 27 2021	BUY Exercise of conversion of derivative security	$371,217 $38.54 p/Share	9,632 Added 41.8%	13,411 Common Stock
Jun 01 2021	SELL Payment of exercise price or tax liability	$20,697 $60.34 p/Share	343 Reduced 8.32%	3,779 Common Stock
Jun 01 2021	BUY Exercise of conversion of derivative security	-	798 Added 16.22%	4,122 Common Stock
Apr 14 2021	SELL Open market or private sale	$98,690 $60.14 p/Share	1,641 Reduced 33.05%	3,324 Common Stock
Apr 14 2021	BUY Exercise of conversion of derivative security	$63,244 $38.54 p/Share	1,641 Added 24.84%	4,965 Common Stock
Apr 13 2021	SELL Open market or private sale	$72,000 $60.0 p/Share	1,200 Reduced 26.53%	3,324 Common Stock
Apr 13 2021	BUY Exercise of conversion of derivative security	$46,248 $38.54 p/Share	1,200 Added 20.96%	4,524 Common Stock
Mar 15 2021	SELL Open market or private sale	$946,706 $52.31 p/Share	18,098 Reduced 84.48%	3,324 Common Stock
Mar 15 2021	BUY Exercise of conversion of derivative security	$300,789 $16.62 p/Share	18,098 Added 45.79%	21,422 Common Stock
Mar 01 2021	SELL Payment of exercise price or tax liability	$75,884 $53.14 p/Share	1,428 Reduced 30.05%	3,324 Common Stock
Mar 01 2021	BUY Exercise of conversion of derivative security	-	2,437 Added 33.9%	4,752 Common Stock
Feb 16 2021	SELL Open market or private sale	$986,522 $54.51 p/Share	18,098 Reduced 88.66%	2,315 Common Stock
Feb 16 2021	BUY Exercise of conversion of derivative security	$300,789 $16.62 p/Share	18,098 Added 46.99%	20,413 Common Stock
Feb 09 2021	SELL Open market or private sale	$494,053 $55.06 p/Share	8,973 Reduced 79.49%	2,315 Common Stock
Feb 09 2021	BUY Exercise of conversion of derivative security	$7,268 $0.81 p/Share	8,973 Added 44.29%	11,288 Common Stock
Jan 26 2021	SELL Open market or private sale	$449,009 $50.04 p/Share	8,973 Reduced 79.49%	2,315 Common Stock

Also insider at

PEAR

Pear Therapeutics, Inc. Healthcare

Director

GLS

GELESIS HOLDINGS, INC. Healthcare

Director

SGHT

Sight Sciences, Inc. Healthcare

Chief Financial Officer